Research programme: CCR5 inhibitors - Consensus

Drug Profile

Research programme: CCR5 inhibitors - Consensus

Alternative Names: CCR5 inhibitors research programme - Consensus

Latest Information Update: 15 Sep 2006

Price : $50

At a glance

  • Originator Consensus Pharmaceuticals
  • Class
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 15 Sep 2006 Discontinued - Preclinical for HIV infections treatment in USA (Injection)
  • 16 Jul 2001 This programme is available for licensing (
  • 13 Apr 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top